Mirum Pharmaceuticals Inc stock is traded at $89.84, with a volume of 48,561. It is down -1.90% in the last 24 hours and up +12.10% over the past month. Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
Previous Close:
$91.58
Open:
$91.00
24h Volume:
48,561
Relative Volume:
0.07
Market Cap:
$5.86B
Revenue:
$569.61M
Net Income/Loss:
-$23.36M
P/E Ratio:
-
EPS:
-$13.60
Net Cash Flow:
$54.87M
1W Performance:
-4.85%
1M Performance:
+12.10%
6M Performance:
-12.08%
1Y Performance:
+24.41%
1-Day Range:
$89.56$92.31
1-Week Range:
$89.56$95.37
52-Week Range:
$63.23$130.00
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Name
Mirum Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
650-667-4085Address
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS